drugset / Trial / NCT03361852
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL). The agents involved in this study are: * Rituximab * Personalized NeoAntigen vaccine * Poly-ICLC * Pembrolizumab
Timeline
- Start
- 2022-03-14
- Primary completion
- 2026-12-31
- Completion
- 2033-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NeoVax | Vaccine | — | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |